30-second key takeaways
- Two studies: JAAD June 2026 published Gregoire et al. (hyperkalemia in women ≥45, n=398) and Dewey et al. (spironolactone + LDOM combination safety, n=432) in the same issue, both from Mass General Brigham retrospective cohorts.
- Hyperkalemia overall 10.1%: in women ≥45 (vs <1% in healthy <45). But 97.5% were mild (5.1-6.0 mEq/L), 85% asymptomatic, 62.5% required no dose change or intervention.
- Risk stratification: age ≥65 22.4% vs 45-64 7.9% (adjusted OR 3.02, 95% CI 1.41-6.49, P=.004); ≥1 predisposing comorbidity (HTN/DM/CKD/CHF) 14.7% vs none 7.3%.
- Highest-risk subgroup: ≥65 + ≥1 comorbidity 28.1% (NNS=5); lowest: healthy 45-64 women 6.3%; not dose-dependent (OR 1.01, P=.349) — 25 mg and 200 mg confer similar risk.
- Timing reversal: FDA label suggests testing within 1-4 weeks, but only 0.8% (3/398) developed hyperkalemia in that window; the average onset was 20.5 months after initiation. The real risk is not the initiation phase, but chronic long-term exposure.
- Spironolactone + LDOM combination: total ADE 37.7%, hypertrichosis 12.3%, orthostatic symptoms 12.0%, edema <5%. 46% needed no intervention; 94.3% managed entirely outpatient.
- Simultaneous vs sequential start: starting both drugs on day 1 reduced hypertrichosis by 64.8% (OR 0.35, 95% CI 0.13-0.94, P=.037) vs sequential initiation, without increasing orthostatic risk. Concurrent use of any other BP-lowering drug raised orthostatic symptom risk 3.29-fold (OR 3.29, 95% CI 1.65-6.58, P=.001).
- Taiwan reality: spironolactone NHI covers only cardio-renal indications (HTN, heart failure, primary aldosteronism, edema); dermatologic uses (acne, female pattern hair loss, hirsutism, hidradenitis suppurativa) are off-label and out-of-pocket. Brand names include 愛達信錠 / 安達通® / Aldactone® / generic spironolactone.
Why these two studies matter
Spironolactone, an aldosterone antagonist approved in 1959 for hypertension, heart failure, primary aldosteronism, and edema, has been used off-label by dermatologists since the 1980s — through its androgen-receptor blockade — for female acne, female pattern hair loss, hirsutism, and hidradenitis suppurativa. The drug label carries a hyperkalemia warning and recommends baseline potassium testing, but that warning derives from the heart-failure RALES trial (1999), not from data on healthy young women in dermatology.
In 2015 Plovanich et al. (JAMA Dermatol) showed <1% hyperkalemia among healthy women <45 on spironolactone for acne, indistinguishable from population background. The 2024 AAD acne guideline therefore concluded that routine potassium monitoring is not needed in healthy young women. But that left an open question — what about older women, or those with comorbidities? Gregoire et al.'s June 2026 JAAD paper is the first cohort study designed specifically to fill that gap for women ≥45.
The companion Dewey et al. study addresses a different clinical pain point: spironolactone is frequently combined with low-dose oral minoxidil (LDOM, not topical) for female hair loss, but the safety literature has only described each drug alone, never the real-world combination. Dewey enrolled 432 women actually on combination therapy and answers three operational questions: is the combination safe overall? Should both drugs start simultaneously or in sequence? Do patients on other BP-lowering drugs need extra caution?
Together these two studies fill the largest grey zone between two prior extremes — "young healthy women" vs "decompensated heart failure" — with real data on peri- and post-menopausal women, with and without comorbidities, on monotherapy or LDOM combination. The clinical implications are direct.
Spironolactone in dermatology: indications and mechanism
Spironolactone has been used off-label in dermatology for 40 years. In the kidney it blocks aldosterone (a potassium-sparing diuretic — the source of the hyperkalemia signal). In skin, it blocks androgen receptors and inhibits 5α-reductase, reducing sebum and follicular androgen response.
Common off-label dermatologic indications and typical dosing:
- Adult female acne, especially jawline / neck cyclic acne. Typical start 25-50 mg/day, may titrate to 100-200 mg/day. 47.5% of Gregoire 2026 cohort had this indication.
- Female pattern hair loss (diffuse vertex thinning). Typical 50-200 mg/day. Comprised 37.4% of Gregoire's cohort and essentially all of Dewey's.
- Hirsutism (terminal hair in male pattern), often with PCOS. Typical 50-100 mg/day. 14.3% of Gregoire's cohort.
- Hidradenitis suppurativa (HS) — recurrent abscesses and sinus tracts in flexures. Spironolactone is a second-line option in female HS. 10.1% of Gregoire's cohort.
Taiwan NHI covers spironolactone only for cardio-renal indications (HTN, primary aldosteronism, heart failure with edema, cirrhotic ascites, hypokalemia). Dermatologic uses (acne, FPHL, hirsutism, HS) are off-label and out-of-pocket. Brand names available locally include 愛達信錠 / 安達通® / Aldactone® / generic spironolactone — this article uses "spironolactone" throughout without endorsing a specific brand.
Study 1: Hyperkalemia in women ≥45 (Gregoire 2026)
Study design
| Item | Detail |
|---|---|
| Design | Single-network, retrospective cohort (no control group) |
| Site / period | Mass General Brigham health network (Boston, MA, USA), Jan 2015 – Feb 2025 |
| Enrollment | 1197 charts screened → 398 analyzed; mean age 54.7 ± 7.9 y; 77.4% white, 85.4% non-Hispanic |
| Indications | Acne 47.5%, FPHL 37.4%, hirsutism 14.3%, HS 10.1%, PCOS 4.5% (some had multiple indications) |
| Comorbidities | 62.3% had no relevant comorbidity; hypertension 32.7%, T2DM 13.1%, CKD 4.3%, CHF 1.0% |
| Concurrent meds | 70.4% no concomitant K+-raising med; β-blocker 13.1%, ACEi 9.5%, thiazide 8.0%, ARB 7.8% |
| Spironolactone dose | Most common starting dose 50 mg (56.8%) or 25 mg (23.9%); most common peak 100 mg (45.2%) or 50 mg (27.9%). 61.8% had at least one dose escalation |
| Hyperkalemia definition | Serum K+ > 5.0 mEq/L (institutional normal 3.5-5.0). Severity: mild 5.1-6.0, moderate 6.1-7.0, severe > 7.0 |
Main results: age × comorbidity risk matrix
Of 398 women ≥45, 10.1% (40) developed hyperkalemia. But the rates diverge dramatically when stratified by age and comorbidity:
Independent risk factors (multivariable logistic regression adjusting for dose, age, comorbidity, concurrent meds, baseline K+ / creatinine):
- Age ≥65: adjusted OR 3.02 (95% CI 1.41-6.49, P=.004), significant.
- ≥1 comorbidity: OR 2.16 (95% CI 0.95-4.91, P=.065), borderline.
- Spironolactone dose: OR 1.01 (95% CI 0.99-1.02, P=.349). Plain English: a 25 mg dose and a 200 mg dose carry statistically indistinguishable hyperkalemia risk.
- Concurrent K+-raising drugs (ACEi/ARB/β-blocker/thiazide): not independently significant in the multivariable model (partly captured via comorbidity OR).
Counter-intuitive finding 1: hyperkalemia timing is not 1-4 weeks but 20 months
One of the paper's biggest clinical implications: the FDA label recommends K+ testing ~1 week after initiation. But of 398 women ≥45, only 3 (0.8%) developed hyperkalemia in the 1-4 week window; the mean time to incident hyperkalemia was 20.5 ± 21.2 months (median 12.5, IQR 3.6-32.5).
This finding inverts the conventional monitoring rationale. If >99% of hyperkalemia events do not occur in the first 4 weeks, then intensive initiation-phase monitoring has low yield. The authors note that hyperkalemia more likely reflects later events — summer dehydration, newly diagnosed HTN starting ACEi, gradually rising creatinine from early CKD. So monitoring should not be concentrated at initiation, but triggered by changes in clinical status.
Counter-intuitive finding 2: hyperkalemia often does not change management
Of 40 patients with documented hyperkalemia:
- 97.5% mild (K+ 5.1-6.0 mEq/L, mean 5.3 ± 0.39). Only one severe case (>7.0); that was attributed to concurrent β-blocker + calcium channel blocker, and spironolactone was continued.
- 85% completely asymptomatic. Reported symptoms were minor: abdominal pain, nausea, fatigue, muscle weakness each 5% (n=2). No lethal arrhythmias, paralysis, or deaths.
- 85% managed outpatient; 10% detected incidentally during admission for other reasons. 1 ED visit then discharge (2.5%); 1 inpatient admission (2.5%); 0 ICU admissions.
- 62.5% had no management change — the clinician reviewed the result and decided no action was needed. 12.5% had dose reduction, 17.5% temporary hold, only 7.5% permanent discontinuation. In other words: only 15/40 (37.5%) of detected hyperkalemia events actually changed therapy.
- 16/40 had a repeat K+ measurement before any spironolactone change; in 75% (12/16), the repeat value normalized — likely lab variation (hemolysis, processing delay).
- In only 15% was spironolactone documented as the primary cause; 55% had uncertain etiology; 25% were attributed to other conditions (dehydration, CKD progression).
There is a large gap between "hyperkalemia incidence" and "clinically meaningful event." Across the whole cohort, only 3.8% (15/398) of all patients had a hyperkalemia event that actually changed management. Even in the highest-risk subgroup (≥65 + ≥1 comorbidity), only 15.6% had a management change. Intensive monitoring "to prevent severe outcomes" mostly detects mild, asymptomatic events that do not change therapy.
Study 2: Safety of spironolactone + LDOM combination (Dewey 2026)
Study design
| Item | Detail |
|---|---|
| Design | Single-network retrospective cohort (no control group — cannot compare to monotherapy) |
| Site / period | Mass General Brigham health network, Jan 2015 – Jun 2025 |
| Enrollment | 621 charts screened → 432 analyzed; mean age at combination start ~47 y (range 18-86); 69.9% white, 81.7% non-Hispanic |
| Indications | All patients had hair-loss diagnoses (androgenetic alopecia, other non-scarring, occasional scarring forms — per ICD-10 coding) |
| Comorbidities | 59.5% no relevant comorbidity; HTN 19.0%, obesity 17.8%, arrhythmia 6.25%, hypotension 2.08%, CKD 1.85%, orthostatic hypotension 0.23% |
| Concurrent meds | 77.8% no concomitant BP-altering med; β-blocker 9.5%, ACEi 5.1%, ARB 3.7%, CCB 3.2%, thiazide 3.2% |
| Spironolactone dose | Most common start 50 mg (51.9%); most common peak 100 mg (38.7%); mean dose at ADE 87.6 ± 51.4 mg |
| LDOM dose | Most common start 1.25 mg (44.9%); most common peak 2.50 mg (44.0%); mean at ADE 1.8 ± 1.1 mg |
| Initiation pattern | Sequential 77.8% (spironolactone first in 79.8%, LDOM first in 20.2%); simultaneous 22.2% |
Adverse-event landscape
163 of 432 (37.7%) reported at least one combination-related adverse effect. Top 5:
Key observations:
- Hypertrichosis (12.3%): the signature LDOM effect. Minoxidil's K+-channel-opener mechanism converts vellus to terminal hair not just on scalp but anywhere — face, arms, forehead. For hair-loss patients, scalp regrowth is the goal but facial hair is unwanted.
- Orthostatic symptoms (12.0%): a combined category of dizziness, lightheadedness, and relative orthostasis. Minoxidil dilates arteries; spironolactone is a diuretic — combined effect is plausible. The observed rate is similar to that reported for LDOM monotherapy, so the combination does not appear to compound this risk dramatically.
- Menstrual changes (7.4%) and breast tenderness (4.2%): known dose-dependent antiandrogen effects of spironolactone, more common at ≥100 mg.
- Edema (4.6%): a known minoxidil effect from sodium retention. Spironolactone's diuretic action should theoretically offset this, but Dewey's data show that offset is incomplete — edema still occurs at 4.6%. Women ≥45 had 3.73× higher edema risk than those <45 (OR 3.73, 95% CI 1.03-13.50, P=.045).
Counter-intuitive: simultaneous vs sequential initiation (hypertrichosis −64.8%)
The most actionable finding: starting spironolactone and LDOM on the same day (simultaneous) was associated with a 64.8% reduction in hypertrichosis compared with starting them sequentially (adjusted OR 0.35, 95% CI 0.13-0.94, P=.037).
The biological hypothesis: minoxidil's vellus-to-terminal conversion requires androgen signaling at the follicle. Spironolactone blocks the androgen receptor and weakens this signaling. Starting both on day 1 means spironolactone is already blocking the signal when LDOM begins pulling vellus hair. But if LDOM runs alone for weeks before spironolactone is added, the vellus-to-terminal transition is already underway and adding spironolactone later cannot reverse it easily.
Critically, simultaneous initiation did NOT increase orthostatic symptoms, edema, or other adverse events — making this a "free" safety optimization. Dewey et al. explicitly recommend simultaneous over sequential initiation for women wishing to minimize hypertrichosis.
Orthostatic risk in patients on concurrent BP-lowering drugs
Another operational finding: women already on any BP-lowering or diuretic drug had 3.29× higher risk of BP-related symptoms (OR 3.29, 95% CI 1.65-6.58, P=.001). This is the strongest actionable risk signal aside from "simultaneous = less hypertrichosis."
Practical implications:
- Before starting combination therapy, actively ask: "Are you taking any blood-pressure medication, diuretic, or anything prescribed by cardiology?" This is more concrete and higher-yield than asking about prior orthostatic hypotension.
- For these patients: start lower, titrate slower, counsel explicitly about "stand up slowly, sit down if dizzy, hold dose if dehydrated." Despite the 3.29× risk increase, no deaths or major adverse events occurred — the risk is at the "reduces quality of life" level, not the "life-threatening" level.
Who needs potassium testing? My stratified recommendations
Mapping Gregoire 2026 data to clinic practice, my suggested stratification (clinical reference only; individualization remains primary):
| Risk tier | Population | K+ rate | Suggested monitoring |
|---|---|---|---|
| Very low | <45, healthy, no comorbidity, no K+-raising meds (AAD 2024 cohort) | <1% | No routine testing; check only on symptoms (severe weakness, lethargy, arrhythmia) |
| Low | 45-64, no comorbidity, no K+-raising meds | 6.3% | One baseline check; no need for intensive follow-up if asymptomatic and no new risk factors |
| Moderate | 45-64 + ≥1 comorbidity; OR ≥65 healthy (including those on ACEi/ARB/β-blocker/thiazide) | 11.0–15.4% | Baseline; 4-6 weeks after reaching peak dose; then every 6-12 months; immediate check if clinical status changes |
| High | ≥65 + ≥1 comorbidity (HTN/DM/CKD/CHF/adrenal insufficiency/cirrhosis/PCOS) | 28.1% | Baseline; 4 weeks post-initiation; 2-4 weeks after every dose escalation; every 3-6 months; check after any dehydration/infection/new med |
Gregoire et al.'s original conclusion: "Clinical decision making around potassium laboratory monitoring should account for age ≥65 and patients' medical complexity. Monitoring guidelines for spironolactone's use in dermatology should be developed over time; for now, individualized clinical decision making is key." The research team explicitly refused to issue a uniform schedule and left the decision to clinicians. The table above is my (Dr Chen Yi-Jia) starting-point synthesis from Gregoire's data and clinical experience — not a guideline. Each patient still requires individualized judgment.
When to draw blood — practical timing
If you decide to monitor, the timing supported by the data differs from the FDA label:
- Baseline (pre-treatment): K+ and creatinine. For high-risk patients, add eGFR; for ≥65, consider baseline ECG (not because of spironolactone but to document baseline rhythm).
- 1-4 weeks after initiation: the FDA label window. Gregoire 2026 shows this window detects only 0.8% of hyperkalemia events — low yield, but still reasonable as a baseline reference, especially for moderate and high-risk groups.
- 2-4 weeks after dose escalation: dose itself is not an independent risk factor (OR 1.01), but escalation is a "clinical status change" signal — a reasonable retest trigger.
- Event-driven testing: the strongest implication of Gregoire's data. Any dehydration (heat, gastro, prolonged exercise without fluids), new comorbidity (HTN/DM/CKD), new medication (ACEi/ARB/β-blocker/thiazide/NSAID/heparin/TMP-SMX), or acute illness — actively retest.
- Long-term routine: not needed for low-risk; every 6-12 months for moderate; every 3-6 months for high-risk. The mean onset was 20 months, so semi-annual checks suffice to catch most events in high-risk patients.
- Repeat before acting: 75% of mildly elevated K+ values normalize on repeat. Unless very high (>6.0) or symptomatic, repeat once before making any spironolactone change.
Practical guidance for spironolactone + LDOM combination
| Scenario | Suggested approach | Rationale |
|---|---|---|
| Young, no comorbidity, doesn't mind facial hair | Either sequence OK (patient preference) | Lowest ADE rate in Dewey's data; some hypertrichosis but acceptable |
| Wants to minimize facial / arm hair | Simultaneous initiation (both day 1) | Simultaneous = 64.8% lower hypertrichosis (OR 0.35, P=.037), no increase in other ADEs |
| On other BP-lowering drug | Low start, slow titration; consider coordination with cardiology | 3.29× orthostatic risk (OR 3.29, P=.001); not contraindicated but needs counseling and monitoring |
| ≥45, history of mild edema | Can use simultaneous; counsel re morning weight, sock marks, ring tightness | ≥45 edema risk 3.73× (OR 3.73, P=.045); spironolactone's diuretic action does not fully offset LDOM |
| History of hypotension / vertigo | Lowest doses (spironolactone 25 mg + LDOM 0.625 mg); frequent follow-up | 2.08% had hypotension and 0.23% orthostatic hypotension in Dewey's cohort — all tolerated but baseline comparison essential |
On dosing: the most common start combination in Dewey was spironolactone 50 mg + LDOM 1.25 mg. Mean dose at ADE was spironolactone 87.6 mg + LDOM 1.8 mg. Escalation: spironolactone +25-50 mg, LDOM +0.625-1.25 mg, reassessed every 4-8 weeks.
Taiwan context: out-of-pocket off-label and brand names
- Taiwan NHI reimburses only cardio-renal indications (HTN / heart failure / primary aldosteronism / cirrhotic ascites / hypokalemia / edema).
- Dermatologic off-label (acne / FPHL / hirsutism / HS): entirely out-of-pocket.
- Approximate cost: generic spironolactone 25 mg ~NT$1-3/tab, 50 mg ~NT$2-5/tab (varies by manufacturer/channel); typical 25-100 mg/day costs roughly NT$100-500/month. Globally recognized as an inexpensive legacy drug.
- Brand names (per local TFDA-approved manufacturers): 愛達信錠 (某 generic 25 mg), 安達通® (some channels), Aldactone® (Pfizer original, may not be imported), other generic spironolactone. This article uses "spironolactone" throughout and does not endorse any specific brand; actual prescribing depends on the clinician's choice and pharmacy stock.
- LDOM is similar: Taiwan NHI covers minoxidil only for severe hypertension (10-40 mg). Low-dose (0.25-5 mg) for hair loss is off-label and out-of-pocket. Common sources: in-house compounding at clinics/hospitals, or splitting/crushing Loniten® 10 mg tablets.
- PCOS patients: in Taiwan, PCOS is generally managed by gynecology or endocrinology. When dermatology prescribes spironolactone for the cutaneous manifestations, co-care with the primary specialty is advised to avoid duplicate prescribing.
Frequently asked questions
Q1. Why did the dermatologist prescribe spironolactone for my acne? Isn't this a blood pressure drug?
Spironolactone was launched in 1959 as a BP drug, but its mechanism has two arms: blocking renal aldosterone (kidney) and blocking androgen receptors (skin). Dermatology uses the second arm — reducing sebum and follicular androgen response — especially effective for adult-female jawline cyclic acne. Off-label use globally for 40 years. In Taiwan, this is off-label and out-of-pocket.
Q2. I'm 25 and healthy — do I need a potassium test?
Per AAD 2024 acne guideline: women <45 with no comorbidity and no K+-raising co-meds (ACEi/ARB/β-blocker/thiazide/NSAID) do not need routine potassium testing. Plovanich 2015 showed <1% hyperkalemia in this group, indistinguishable from background. Test only if severe muscle weakness, arrhythmia, or syncope develops.
Q3. My mother is 70 and the dermatologist wants to prescribe spironolactone for her hair loss — is it safe?
This is exactly the population Gregoire 2026 was designed for. Among women ≥65, hyperkalemia overall 22.4% (28.1% if any comorbidity). But 97.5% mild, 85% asymptomatic — the issue is monitoring + coordination, not contraindication. Suggested: (1) baseline K+, creatinine, eGFR; (2) 4-week recheck; (3) every 3-6 months thereafter; (4) check after dehydration or new medication. Start lower than in younger women (25 mg/day, slow titration). If she's already on ACEi/ARB/β-blocker, coordinate with cardiology first.
Q4. I've been on it for a year without any issue — do I still need to monitor?
This is Gregoire 2026's most counter-intuitive finding. Mean onset of hyperkalemia is 20.5 months (median 12.5), not the initiation phase. "Stable for one year" does not mean "stable forever." Low-risk groups (45-64, healthy, no comorbidity) genuinely don't need intensive surveillance; but moderate- and high-risk groups should keep periodic checks, especially at any clinical change (summer dehydration, GI illness, new BP medication, slow creatinine rise from early CKD).
Q5. I'm on a BP medication and spironolactone — what should I watch?
Two separate concerns: (1) Hyperkalemia: ACEi / ARB / NSAID / heparin / TMP-SMX all raise K+; combined with spironolactone they need more frequent monitoring (moderate-to-high tier). (2) Orthostatic symptoms: Dewey 2026 showed 3.29× higher risk of dizziness / lightheadedness / relative hypotension when LDOM + spironolactone is combined with any other BP-lowering drug. Counseling: stand up slowly, sit down if dizzy, hydrate in summer / after exercise, sit on bed edge 30 sec before standing. If orthostasis interferes with daily life, discuss BP medication adjustment with cardiology.
Q6. Why do some doctors start both drugs together while others stagger them?
Before Dewey 2026 there was no clear guidance. The study found 77.8% of clinicians used sequential and 22.2% simultaneous initiation. With the new data, simultaneous is more strongly preferable — 64.8% lower hypertrichosis with no increase in other risks. If facial hair concerns you, discuss day-1 simultaneous initiation. If LDOM ran alone for a while before spironolactone was added, the vellus-to-terminal conversion may already be underway and later-added spironolactone may have limited reversal effect.
Q7. Will I get menstrual irregularities or breast tenderness?
Yes, known dose-dependent antiandrogen effects. Dewey 2026 reported breast tenderness 4.2%, menstrual changes 7.4%; more common at ≥100 mg/day. Most patients tolerate or accommodate over time. If intolerable, consider: (1) dose reduction (try 25-50 mg); (2) add oral contraceptive (if appropriate, after excluding VTE/smoking contraindications); (3) switch to a different antiandrogen. Avoid pregnancy — spironolactone has potential feminizing effects on male fetuses; when planning pregnancy, discontinue and use contraception.
Q8. What about pregnancy planning?
Because of its antiandrogen activity, spironolactone could theoretically cause feminization or under-virilization of male fetuses. Human data on actual teratogenic risk are limited, but the consensus is "discontinue before trying to conceive." Suggested: stop 1-3 months before attempting pregnancy; use contraception during treatment (OCP, condom, IUD). LDOM should also be avoided during pregnancy. If unplanned pregnancy occurs, discuss with obstetrics promptly — discontinuation is usually sufficient (not an indication for termination), but disclose the medication history at prenatal visits.
Common myths
Myth 1: "Spironolactone is a BP drug — dermatologists shouldn't prescribe it."
It's both a BP drug AND an antiandrogen. Dermatology has prescribed it off-label for 40 years; AAD 2024 acne guideline explicitly lists it as a hormonal-therapy option. In Taiwan it's not on NHI for dermatology indications, but remains legal off-label prescribing at the physician's discretion, paid out-of-pocket. The question is not "may we prescribe" but "how to prescribe safely" — which is exactly what Gregoire 2026 and Dewey 2026 address.
Myth 2: "The higher the dose, the worse the hyperkalemia."
Gregoire 2026's multivariable analysis showed dose is not an independent risk factor (OR 1.01 per mg, P=.349). 25 mg and 200 mg confer statistically similar hyperkalemia risk. The dose distribution among hyperkalemia events mirrors the overall prescribing distribution — no dose-response relationship. Risk is driven by age + comorbidity, not by spironolactone dose itself.
Myth 3: "The label says check at 1 week, so weekly checks are safest."
The FDA label's timing derives from 1990s heart-failure data. Gregoire 2026 shows that in dermatologic patients ≥45, only 0.8% develop hyperkalemia in the 1-4 week window; mean onset is 20.5 months. Initiation-phase intensive monitoring has low yield. A "periodic + event-driven" strategy is more practical. The authors are clear: this is not about abandoning monitoring, but about putting monitoring where it pays off.
Myth 4: "Starting two drugs at once is more dangerous — always stagger."
Intuitive — but Dewey 2026 disproves it with data. Women starting spironolactone + LDOM on day 1 had 64.8% lower hypertrichosis with NO increase in orthostatic symptoms, edema, or any other adverse event. Why? The two drugs have different ADE mechanisms: spironolactone's antiandrogen effect "immediately offsets" the minoxidil-induced vellus-to-terminal transition. If LDOM runs alone for 4-8 weeks first, the conversion is already underway and adding spironolactone later won't reverse it. (That said, for patients prone to orthostasis, slow titration from low doses remains reasonable.)
Advanced: notes for clinical colleagues
Read together, these two studies surface several tensions worth thinking through:
First, label-timing vs real-world timing. The FDA label's 1-week recommendation derives from the 1999 RALES trial (severe heart failure, mostly eGFR <60, mean age 70, 25% mortality). Gregoire 2026's dermatology population is fundamentally different — younger-to-middle-aged women, no heart failure, mostly normal eGFR. Transplanting RALES's monitoring schedule onto a dermatology population is misapplying "initiation-phase risk in a critically ill cohort" to "chronic-phase risk in a relatively healthy cohort." What dermatology actually needs is "annual check + event-driven retest."
Second, the 80% gap between "lab abnormality" and "clinically meaningful." Of 40 hyperkalemia cases: 62.5% needed no change in spironolactone, 12 patients with repeats normalized, and only 15% had hyperkalemia attributed primarily to spironolactone. A K+ of 5.3 is not, by itself, a clinical event. The first action should be (1) repeat, (2) assess dehydration / acute illness, (3) review concurrent medications — not immediate discontinuation. Hill 2024 (IJDVL) reached the same conclusion: "Frequent monitoring detects hyperkalemia that is mostly clinically insignificant."
Third, the mechanism behind "simultaneous = less hypertrichosis." The 64.8% reduction is unlikely to be a simple "effects cancel out" — more plausibly, the two drugs establish follicular signaling cross-talk earlier when started together. LDOM opens follicular K+ channels, prolongs anagen, and converts vellus to terminal hair; spironolactone blocks AR and weakens the androgen signal required for that conversion. If spironolactone occupies AR on day 1, the LDOM-driven vellus-to-terminal transition is dampened from the start. But if LDOM runs alone for 4-8 weeks first, terminal hair has already established anagen architecture; adding spironolactone later blocks the androgen signal but cannot reverse the already-formed terminal hair structure. This is Dewey's hypothesis, not experimentally proven — but its clinical implication for prescribing is already sufficient.
Fourth, study limitations. Both are single-network retrospective cohorts with no control group — causality cannot be established; both populations are >70% white, limiting extrapolation to Asian populations. Gregoire lacked a contemporaneous <45 spironolactone control; Dewey lacked monotherapy controls for both drugs. Even so, these are among the best real-world data available; the next step is prospective randomization to confirm whether the "simultaneous = less hypertrichosis" signal replicates.
Fifth, applicability to Taiwan. Taiwanese women <45 commonly take spironolactone for acne, in line with US data. Few Taiwan-specific studies exist on dermatologic spironolactone in women ≥45, but the physiology is the same. Asian women have lower mean BMI than the US cohort, different CKD prevalence, and different dehydration patterns (summer heat, humidity in northern Taiwan). Clinically, Gregoire / Dewey can be used as "reasonable starting recommendations," not as a directly transferable guideline; Asia-specific data are still needed.
Takeaway: what you can do
If you're a woman taking or considering spironolactone:
- <45, healthy, no comorbidity: spironolactone's safety is excellent; routine K+ testing usually not needed. Tell your doctor if severe muscle weakness, palpitations, or fainting occurs.
- 45-64, healthy, no comorbidity: ~6% hyperkalemia, mostly mild. One baseline K+ is enough; thereafter per physician (often yearly) and at any clinical change.
- ≥65 or with comorbidity (HTN/DM/CKD/cardiac): discuss a stratified monitoring plan with the dermatologist; inform your primary care / cardiology / nephrology that you're on spironolactone to avoid duplicate prescribing and interactions.
- Combining spironolactone + LDOM for hair loss: discuss simultaneous initiation with your dermatologist (64.8% lower hypertrichosis). If you're on any other BP medication, mention it; expect a lower starting dose and closer follow-up.
- Planning pregnancy: stop spironolactone (and LDOM) 1-3 months before attempting to conceive; use contraception while on therapy.
- On therapy >1 year: don't relax just because nothing has happened yet. Mean onset of hyperkalemia is 20 months. Inform your doctor at any clinical change (severe summer dehydration, GI illness, new medications, comorbidity progression) and retest as needed.
For colleagues: read together, the two JAAD 2026 studies offer "more refined risk stratification" and "more actionable combination prescribing." But both authors emphasize that individualization is irreplaceable, and Gregoire deliberately refused to issue a uniform monitoring schedule. Gregoire's data suggest: (1) align monitoring intensity with age + comorbidity; (2) recognize that dose is not the main driver of spironolactone-related hyperkalemia; (3) shift the monitoring focus from "1-4 weeks post-initiation" to "event-driven retesting." Dewey offers two actionable rules: "simultaneous initiation = less hypertrichosis" and "concurrent BP-lowering drug = closer orthostatic monitoring." All else must return to individual patient context.
References
- Gregoire S, Dewey E, Sanchez K, et al. Hyperkalemia incidence in females over 45 years old on spironolactone for dermatologic conditions: A retrospective cohort study. J Am Acad Dermatol. 2026;94(6):1671-1678. DOI: 10.1016/j.jaad.2026.02.009
- Dewey E, Salloum L, Gregoire S, et al. Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study. J Am Acad Dermatol. 2026;94(6):1679-1685. DOI: 10.1016/j.jaad.2026.02.003
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30.
- Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941-944.
- Plante J, Robinson I, Elston D. The need for potassium monitoring in women on spironolactone for dermatologic conditions. J Am Acad Dermatol. 2022;87(5):1097-1099.
- Hill RC, Wang Y, Shaikh B, Christos PJ, Lipner SR. Frequent potassium monitoring is associated with hyperkalemia that is clinically insignificant in females taking spironolactone for dermatologic conditions. Indian J Dermatol Venereol Leprol. 2024;90:659-661.
- Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169-191.
- Wang Y, Lipner SR. Retrospective analysis of adverse events with spironolactone in females reported to the United States food and drug administration. Int J Womens Dermatol. 2020;6(4):272-276.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Nohria A, Desai D, Sikora M, et al. To evaluate hypertrichosis with low dose oral minoxidil and spironolactone combination therapy for alopecia. Arch Dermatol Res. 2024;316(8):1-3.
- Jimenez-Cauhe J, Gil-Redondo R, Saceda-Corralo D, et al. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. J Am Acad Dermatol. 2025;92(6):e197-e198.
- Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023;15(8):e43559.
- Taiwan Food and Drug Administration. Spironolactone (Aldactone®) Drug Label and Approval Information. https://www.fda.gov.tw/
- Taiwan NHI Administration. NHI Drug Reimbursement Policy (spironolactone cardiovascular and renal indications). https://www.nhi.gov.tw/